11/11/2025
Yesterday was a GREAT DAY - removal of the black box warning for estrogen by the FDA….its about time!
🤩”This is, in my opinion, one of the greatest mistakes in modern medicine — the demonization of hormone replacement therapy,” FDA Commissioner Dr. Marty Makary said Monday.
13-87% of women experience genital/urinary symptoms and only 50% of women are taking about with their provider!!! Time for that to change! Read the guidelines and info below and TALK TO YOUR PROVIDER, especially if you are worried about family history risk.
History: Ge***al Symptoms of Menopause (GSM) prevalence estimates in postmenopausal patients vary widely from 13 to 87 percent. This inconsistency stems from many factors including variation in the symptoms and/or signs assessed and evaluated, the symptom assessment tools used, and the demographics and settings of study populations. Unlike vasomotor symptoms of menopause (i.e., hot flashes and/or night sweats), the prevalence and intensity of some genitourinary symptoms, such as vulvovaginal dryness, increase with advancing age. GSM may be associated with reduced quality of life (QoL) and sexual functioning, and a higher likelihood of urinary complaints, all of which may interfere with interpersonal relationships. Despite the potentially disruptive nature of GSM, only about half of individuals with GSM symptoms report discussing their symptoms with their clinicians, and of those who did, most said the clinician did not initiate the conversation.
We can help!!! Schedule a call or send us a message!
Guidelines: Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025) - American Urological Association
Endorsed by The International Society for the Study of Women’s Sexual Health (ISSWSH), The Sexual Medicine Society of North America (SMSNA), and The Menopause Society (TMS)
